| Literature DB >> 26423050 |
Maaike G E Fenten1, Karin P W Schoenmakers1, Petra J C Heesterbeek2, Gert Jan Scheffer1, Rudolf Stienstra3.
Abstract
BACKGROUND: In what way volume, concentration and dose affect block duration is controversial. The purpose of the present study is to investigate the effect of dose, volume and concentration of mepivacaine on the duration of sensory and motor blockade in ultrasound-guided single shot axillary brachial plexus blockade.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26423050 PMCID: PMC4588252 DOI: 10.1186/s12871-015-0110-0
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Baseline characteristics
| Group A ( | Group B ( | Group C ( | |
|---|---|---|---|
| Sex, no. M/ no. F | 2/13 | 6/9 | 7/8 |
| Age (yr) | 59 ± 9 | 49 ± 13 | 53 ± 15 |
| Height (cm) | 165 ± 7 | 172 ± 8 | 171 ± 11 |
| Weight (kg) | 71 ± 13 | 75 ± 7 | 78 ± 17 |
| ASA classification, no. 1/no. 2/ no. 3 | 3/10/2 | 10/5/0 | 7/8/0 |
| Duration of surgery (min) | 24 ± 17 | 27 ± 25 | 34 ± 27 |
| Site of surgery, no. left/ no. right | 5/10 | 5/10 | 5/10 |
| Type of surgery: | |||
| - carpal tunnel release, no. | 3 | 2 | 4 |
| - trapezoidectomy, no. | 6 | 1 | 2 |
| - removemal of osteosynthesis material, no. | 2 | 4 | 1 |
| - arthrodesis of finger, no. | 0 | 2 | 1 |
| - release trigger finger, no. | 2 | 2 | 3 |
| - arthrodesis of wrist, no. | 0 | 1 | 2 |
| - other, no. | 2 | 3 | 2 |
Group A: 20 mL mepivacaine 1.5 %. Group B: 30 mL mepivacaine 1.0 %. Group C: 30 mL mepivacaine 1.5 %. Values are absolute numbers, mean ± SD
Fig. 1Flowchart of patients enrolled in the study
Block scores of individual nerves at 30 minutes
| Group A ( | Group B ( | Group C ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Nerve | Score 2 | Score 1 | Score 0 | Score 2 | Score 1 | Score 0 | Score 2 | Score 1 | Score 0 |
| Med. Anteb. Cut. sens | 14 | 1 | – | 14 | 1 | – | 15 | – | – |
| Musculocutaneous sens | 13 | 2 | – | 14 | 1 | – | 15 | – | – |
| Musculocutaneous mot | 13 | 2 | – | 12 | 3 | – | 14 | 1 | – |
| Radial sens | 14 | 1 | – | 10 | 5 | – | 14 | 1 | – |
| Radial mot | 14 | 1 | – | 12 | 2 | 1 | 13 | 2 | – |
| Median sens | 14 | 1 | – | 12 | 3 | – | 15 | – | – |
| Median mot | 13 | 2 | – | 14 | 1 | – | 15 | – | – |
| Ulnar sens | 14 | 1 | – | 13 | 1 | 1 | 14 | 1 | – |
| Ulnar mot | 14 | 1 | – | 14 | 1 | – | 15 | – | – |
Group A: 20 mL mepivacaine 1.5 %; Group B: 30 mL mepivacaine 1.0 %; Group C: 30 mL mepivacaine 1.5 %. Med. anteb. cut.: medial antebrachial cutaneous nerve; sens: sensory block score, mot: motor block score. Block was scored on a three-point scale as 0 = absent, 1 = partial and 2 = complete
Duration of axillary plexus nerve block
| Group A ( | Group B ( | Group C ( |
| |
|---|---|---|---|---|
| Block duration (min) | ||||
| Overall sensory | 256 (230 – 282) | 226 (209 – 243) | 270 (248 – 291) |
|
| Overall motor | 254 (226 – 282) | 220 (200 – 240) | 264 (244 – 284) |
|
| Block duration (min) | ||||
| Med. Anteb. Cut. nerve | ||||
| Sensory | 222 (201 – 242) | 197 (174–220) | 247 (221 – 273) |
|
| Musculocutaneous nerve | ||||
| Sensory | 213 (191 – 235) | 196 (175 – 217) | 215 (186 – 244) | 0.446 |
| Motor | 224 (206 – 242) | 188 (164 – 212) | 216 (197 – 236) |
|
| Radial nerve | ||||
| Sensory | 228 (197 – 259) | 207 (190 – 223) | 227 (191 – 164) | 0.328a |
| Motor | 229 (206 – 251) | 209 (190 – 229) | 258 (238 – 277) |
|
| Median nerve | ||||
| Sensory | 236 (211 – 261) | 204 (185 – 223) | 248 (224 – 272) |
|
| Motor | 245 (214 – 275) | 200 (175 – 225) | 241 (222 – 259) |
|
| Ulnar nerve | ||||
| Sensory | 238 (211 – 265) | 211 (189 – 233) | 249 (220 – 278) | 0.087 |
| Motor | 243 (211 – 274) | 209 (185 – 234) | 257 (236 – 279) |
|
Group A: 20 mL mepivacaine 1.5 %; Group B: 30 mL mepivacaine 1.0 %; Group C: 30 mL mepivacaïne 1.5 %; med. anteb. cut. nerve: medial antebrachial cutaneous nerve. ano data because of a postoperative cast or bandage in 6 patients in Group A, 5 patients in Group B and 8 patients in Group C. bno data because of a postoperative cast or bandage in 3 patients in group A, 2 patients in Group B and 2 patients in Group C. Values are mean (95 % CI)
Bold data represent statistically significant differences
Fig. 2Duration of overall sensory block (a) and overall motor block (b) per Group. Group A: 20 mL mepivacaine 1.5 %. Group B: 30 mL mepivacaine 1.0 %. Group C: 30 mL mepivacaine1.5 %. Dots represent individual patients, the horizontal lines with error bars represent mean with SD. *p < 0.05
Groupwise comparisons of block duration
| Group A vs Group B | Group B vs Group C | Group A vs Group C | ||||
|---|---|---|---|---|---|---|
| Difference (95 % CI) |
| Difference (95 % CI) |
| Difference (95 % CI) |
| |
| Block duration (min) | ||||||
| Overall sensory | 30 (−5 – 65) | 0.100 |
|
| −14 (−49 – 21) | 0.599 |
| Overall motor | 34 (−3 – 70) | 0.079 |
|
| −10 (−47 – 27) | 0.787 |
| Block duration (min) | ||||||
| Med. Anteb. Cut. nerve | ||||||
| Sensory | 24 (−13 – 62) | 0.260 |
|
| −25 (−63 – 12) | 0.244 |
| Musculocutaneous nerve | ||||||
| Sensory | 17 (−22 – 56) | 0.550 | −19 (−58 – 20) | 0.482 | −2 (−41 – 37) | 0.993 |
| Motor |
|
| −28 (−61 – 5) | 0.110 | 7 (−26 – 41) | 0.848 |
| Radial nerve | ||||||
| Sensory | 22 (−18 – 61) | 0.375 | −21 (−63 – 22) | 0.451 | 1 (−43 – 44) | 0.999 |
| Motor | 20 (−13 – 52) | 0.320 |
|
| −29 (−62 – 3) | 0.086 |
| Median nerve | ||||||
| Sensory | 32 (−4 – 69) | 0.091 |
|
| −12 (−48 – 24) | 0.709 |
| Motor |
|
|
|
| 4 (−35 – 44) | 0.963 |
| Ulnar nerve | ||||||
| Sensory | 27 (−15 – 70) | 0.272 | −38 (−80 – 4) | 0.082 | −11 (−53 – 32) | 0.818 |
| Motor | 34 (−8 – 76) | 0.137 |
|
| −15 (−57 – 28) | 0.684 |
Group A: 20 mL mepivacaine 1.5 %. Group B: 30 mL mepivacaine 1.0 %. Group C: 30 mL mepivacaine 1.5 %; med. anteb. cut. nerve: medial antebrachial cutaneous nerve; CI: confidence interval. Values are calculated differences (95 % confidence interval of the difference). Multiplicity adjusted p-values are given
Bold data represent statistically significant differences
Fig. 3Combined data on sensory block duration (a) and motor block duration (b) of the present study and 13 patients receiving 15 mL and 15 patients receiving 40 mL mepivacaine 1.5 % from previously published work [7]. Data are presented as mean with SD. *p < 0.005